SynthesisFrontiers in psychiatry2022
Dropout Rates in Psychosocial Interventions for People With Both Severe Mental Illness and Substance Misuse: A Systematic Review and Meta-Analysis.
Synthesis in Frontiers in psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Effectiveness of psychosocial interventions for adults with substance use disorder that have a co-occurring mental health disorder: an umbrella review and illustrative cost-effectiveness analysis.Health technology assessment (Winchester, England) · 2026Pooled it
- Chatbot interventions for improving mental health among people in Asia: a systematic review and meta-analysis of randomised controlled trials.BMJ health & care informatics · 2026Pooled it
- Prevalence of Dropout and Influencing Factors in Digital Psychosocial Intervention Trials for Adult Illicit Substance Users: Systematic Review and Meta-Analysis.Journal of medical Internet research · 2025Pooled it
- Trial
- Avatar Intervention in Virtual Reality for Cannabis Use Disorder in Individuals With Severe Mental Disorders: Results From a 1-Year, Single-Arm Clinical Trial.JMIR mental health · 2024Trial
- The Young Ones, pre-post results of a transdiagnostic ACT-training for adolescents with Severe Mental Illness.Community mental health journal · 2026Article
- Preliminary Evidence on the Efficacy and Tolerability of Quetiapine in Dual Disorders: A Prospective, Multicentric, Real-World Study.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Substance Use Disorders and the Psychosis Spectrum: Assessment, Clinical Challenges and Management.Journal of clinical medicine · 2026Review
- Ketogenic metabolic therapy as a candidate adjunct for CBTp delivery in schizophrenia spectrum disorders.Frontiers in psychology · 2026Article
- Recovery Outcomes and Treatment Dropout in Patients with Complex Problems Undergoing Inpatient Addiction Treatment: A Naturalistic Prospective Cohort Study.European addiction research · 2026Article
- Equine-assisted coaching in formerly incarcerated men with histories of substance abuse: a 12-week exploratory study of anger regulation, quality of life, human-horse synchrony, and equine behavior.Frontiers in psychology · 2026Article
- Assessment of alcohol and tobacco use in psychotherapy: validation of the german self-report ASSIST alcohol and tobacco subscales in an outpatient setting.Addictive behaviors reports · 2025Article
- Digital Contingency Management for Substance Use Disorder Treatment: 12-Month Quasi-Experimental Design.JMIR mental health · 2025Article
- Effects of Anxiety Focused Nursing Interventions on Anxiety, Cognitive Function and Delirium in Neurocritical Patients: A Non-Randomized Controlled Design.Nursing in critical care · 2025Article
- SIPD or psychotic disorder with stimulant use.Schizophrenia research. Cognition · 2025Article
- Article
- Discontinuities in and Perceptions of Mental Health Service Path of Violent Young Offenders: A Qualitative Descriptive Study.Community mental health journal · 2025Article
- A proof-of-concept analysis of data from the first NHS clinic for young adults with comorbid cannabis use and psychotic disorders.BJPsych open · 2024Article
- Management of schizophrenia and comorbid substance use disorders: expert review and guidance.Annals of general psychiatry · 2024Review
- Investigating the Effectiveness of Brexpiprazole in Subjects with Schizophrenia Spectrum Illness and Co-Occurring Substance Use Disorder: A Prospective, Multicentric, Real-World Study.Pharmaceuticals (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Over the years, many psychosocial interventions for individual having both a psychotic spectrum disorder and a substance use disorder diagnoses have been developed and studied. However, there is a high dropout rate among this clinical population. Objectives: This meta-analysis aims to replicate a previous meta-analysis on the effects of psychosocial treatment for dual disorders, while including and determining the dropout rates in those type of interventions. Method: Based on a Cochrane systematic review conducted in 2019, we conducted a meta-analysis including 40 randomized clinical trials on psychosocial treatment among persons suffering from schizophrenia spectrum disorder and substance use disorder. Results: A dropout rate of 27,2% was obtained. Stimulants use significantly affected dropout rates. Age, gender, diagnosis, alcohol and cannabis abuse, and duration of treatment did not affect dropout rates. Conclusion: The 27,2% rate of dropout from psychosocial treatment highlights the need to engage participants having a dual diagnosis from the start by focusing on therapeutic alliance and motivation for treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.